Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
Inspira (Nasdaq: IINN) reported full-year 2025 results and business updates on March 26, 2026, highlighting clinical validation and early commercial traction for the INSPIRA ART100 system.
Key points: $289k 2025 revenue from initial deployments, $49.5M binding purchase orders secured in mid-2025 expected to convert to 2026 revenue, R&D $7.496M, operating loss $13.22M, cash $3.159M at year-end, and a subsequent $4.75M registered direct offering boosting liquidity.
Inspira (NASDAQ: IINN, IINNW) received a Nasdaq notice dated Feb 19, 2026, that it is not in compliance with Listing Rule 5550(b)(2) requiring a minimum market value of publicly held shares of $35,000,000.
The company has a 180-day cure period through Aug 18, 2026, to regain compliance by closing at or above $35,000,000 for 10 consecutive business days; trading of ordinary shares continues on Nasdaq.
Inspira Technologies (NASDAQ: IINN, IINNW) deployed its FDA-cleared ART100 system at a leading New York academic medical center ranked in the state top 10. The system was integrated into clinical workflow to begin a structured commercial evaluation aimed at defining protocols and wider institutional adoption.
This deployment expands Inspira's presence in Tier-1 U.S. hospitals and supports the company's ongoing U.S. commercial strategy and evaluations at other major healthcare facilities.
Inspira Technologies (NASDAQ: IINN) will showcase its FDA-cleared ART100 at AmSECT 64th International Conference, March 25–29, 2026, in Austin, Texas, via U.S. distributor Glo-Med Networks.
The company is targeting perfusionists and cardiac surgical teams to accelerate U.S. commercial adoption, leveraging its FDA 510(k) clearance (May 2024) and active distribution channel for clinical integration.
Inspira Technologies (NASDAQ: IINN) received a Nasdaq written notification on Feb 9, 2026, for failing to meet the $1.00 minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The company has a 180-calendar-day compliance period until Aug 10, 2026, to regain compliance by achieving a $1.00 closing bid for ten consecutive business days; shares continue to trade on Nasdaq during this period.
Inspira Technologies (NASDAQ: IINN) secured vendor approval from the Medical Equipment Committee of Clalit Health Services, enabling immediate procurement and deployment of the INSPIRA ART100 across Clalit's network serving approximately 4.9 million members.
The approval covers 14 major hospitals and over 1,600 clinics, follows a technical and clinical review by the relevant professional committee, and positions the ART100 for commercial use within one of the world’s largest integrated HMOs.
Inspira (NASDAQ: IINN, IINNW) priced a registered direct offering of 6,785,715 ordinary shares at $0.70 per share, expected to raise approximately $4.75 million gross, plus a concurrent private placement of unregistered warrants to purchase up to 6,785,715 shares.
The warrants have an exercise price of $0.70, become exercisable six months after issuance, and expire 5.5 years from issuance. Closing is expected on or about February 6, 2026. The company also agreed to amend certain existing warrants to a $0.70 exercise price.
Inspira Technologies (NASDAQ: IINN) validated its Next-Generation Standalone HYLA blood sensor, reporting 94.2% accuracy for continuous pCO₂ measurement concordant within a 7 mmHg threshold. The standalone configuration targets an immediate commercial pathway into the ~$48 billion heart-lung surgery market and plans a U.S. FDA submission in 2026. The strategy emphasizes disposable optical sensors and modular software for recurring revenue and broader OR/ICU integration.
Inspira Technologies (NASDAQ: IINN) announced its FDA-cleared INSPIRA ART100 completed full clinical evaluation and moved from pilot use to routine workflow at a top U.S. academic medical center.
Approximately 30 patients were treated across multiple indications and the hospital has begun a budgeted procurement process for multiple ART100 systems.
Inspira (NASDAQ: IINN) said two previously announced binding purchase orders — $22.5 million (July 2, 2025) and $27 million (August 19, 2025) — have advanced to the final budgetary validation and fund allocation stage within relevant governmental procurement processes.
The company reported that ~91% of the orders have cleared commercial and administrative review and are undergoing the concluding budgetary authorization step prior to fund release and execution. Inspira expects payment and revenue recognition during the 2026 fiscal cycle, subject to customary governmental approvals, and says internal execution preparations are complete.